Concord Medical(US:CCM) Jin Rong Jie·2025-08-11 15:59Core Insights - Taihe Cheng Medical (CCM) experienced an intraday increase of 8.63%, closing at $5.54 per share with a total market capitalization of $27.4879 million [1] - As of December 31, 2024, the company's total revenue is projected to be 384 million RMB, reflecting a year-on-year decrease of 28.55%, while the net profit attributable to the parent company is expected to be -30.8 million RMB, a decline of 3.56% year-on-year [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services and is jointly recommended by JP Morgan, Morgan Stanley, and CICC [1] - Established in 1997, the company specializes in cancer prevention, diagnosis, education, and research, offering third-party tumor imaging diagnosis and radiation therapy services, as well as operating specialized cancer hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on various aspects such as diagnostic technology, radiation quality control, medical processes, operational management, brand usage in Singapore and mainland China, and the operation and training of proton centers [1] - The collaboration aims to build an international specialized cancer hospital based on a multidisciplinary diagnostic model and clinical research orientation, enhancing patient experience and improving cancer diagnosis and treatment standards in China [1]